Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9570442 | 0.79 | TSHR (0.63) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL17826781 | 0.78 | TSHR (0.48) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL6689545 | 0.76 | TSHR (0.75) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL3313657 | 0.75 | PPARD (0.70) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL5961215 | 0.75 | TSHR (1.00) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL26483 | 0.75 | TSHR (1.00) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL282472 | 0.75 | TSHR (0.67) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL28615546 | 0.74 | PPARD (0.54) | TSHRPPARDTP53TDP1 | |
| SCHEMBL9654507 | 0.73 | TSHR (0.63) | TSHRPPARDTP53TDP1MEN1 | |
| SCHEMBL11745101 | 0.73 | TSHR (0.94) | TSHRPPARDTP53TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015051874-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ZENTIVA, K.S. (CZ) | 2015-04-16 | — | — | WO | claimed |
| EP-2860185-A1 | An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof | Zentiva, k.s. (CZ) | 2015-04-15 | — | — | EP | claimed |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025096957-A1 | RAS-PI3K INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119677716-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | VIVIDION THERAPEUTICS, INC. | 2025-01-07 | — | — | US | disclosed |
| EP-0762883-A1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 1997-03-19 | — | — | EP | disclosed |
| US-5574024-A | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | EBETINO FRANK H (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1995033466-A1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 1995-12-14 | — | — | WO | disclosed |
| EP-0663919-A1 | PYRIMIDINE BISPHOSPHONATE ESTERS AS ANTI-INFLAMATORIES | PHARMACIA & UPJOHN COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| CN-1098715-A | PLA 2 inhibitors 1H-indole-3-acetamide compounds | LILLY CO ELI (US) | 1995-02-15 | — | — | CN | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| WO-1994009017-A1 | PYRIMIDINE BISPHOSPHONATE ESTERS AND (ALKOXYMETHYLPHOSPHINYL)ALKYL PHOSPHONIC ACIDS AS ANTI-INFLAMMATORIES | THE UPJOHN COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0298553-B1 | METHYLENE PHOSPHONOALKYLPHOSPHINATES, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | Norwich Eaton Pharmaceuticals, Inc. (US) | 1992-01-15 | — | — | EP | disclosed |
| EP-0298553-A1 | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | Norwich Eaton Pharmaceuticals, Inc. (US) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | TSHR 2577/4885PPARD 2857/4885TP53 149/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | TSHR 2756/4885PPARD 3300/4885TP53 2516/4885 |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | TSHR 919/4885PPARD 1446/4885TP53 1409/4885 |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | RECQL, BLM, WRN | TSHR 4064/4885PPARD 3372/4885TP53 7/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | TSHR 4064/4885PPARD 3372/4885TP53 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.